Bagel Labs Begins Clinical Trial of AI-Based Rehabilitation Coaching Digital Therapeutic 'DEX-2'

원본보기 아이콘

Bagel Labs, a company specializing in digital therapeutics, announced on November 11 that it has officially launched an investigator-initiated clinical trial to verify the clinical effectiveness of its musculoskeletal rehabilitation digital therapeutic device, 'DEX-2,' in collaboration with Professor Kim Kwangil from the Department of Geriatrics and Professor Lim Jaeyoung and Professor Bum Jaewon from the Department of Rehabilitation Medicine at Seoul National University Bundang Hospital.

Bagel Labs is a healthcare subsidiary of Xperix, an artificial intelligence (AI) solutions company, and has independently developed an AI-based video recognition solution for this clinical trial.

'DEX-2' is a next-generation digital rehabilitation treatment platform that both institutions have been jointly developing since 2022. It features real-time, precise monitoring of patients' joint movements using AI-based video recognition technology, and provides automatic feedback on posture and exercise repetitions.

Users can easily perform rehabilitation exercises at home by following the exercise demonstrations of a therapist on a TV screen using only the front camera of a smartphone, without any additional equipment.

In particular, 'DEX-2' uses AI to automatically assess the user's physical abilities and provides customized exercise programs, adjusting the difficulty level in real time according to each individual's condition. In addition, key movements such as Sit-to-Stand and Heel-Raise are linked with dedicated hardware, enabling older adults who are less familiar with smartphones to easily record repetitions and consistently continue rehabilitation exercises in their daily lives.

This clinical trial will evaluate the effects of DEX-2's exercise intervention on approximately 120 patients across three major musculoskeletal disease groups: sarcopenia, osteoporosis, and knee osteoarthritis. There is especially high anticipation regarding whether DEX-2 can establish itself as a new non-pharmacological treatment alternative in the field of sarcopenia, for which there is currently no effective medication.

Park Suhong, CEO of Bagel Labs, stated, "DEX-2 is not just a simple rehabilitation aid, but an AI coaching solution that evolves based on the user's movement data. Through this clinical trial, we aim to prove that digital therapeutics can serve as a practical alternative for the prevention and management of musculoskeletal diseases such as sarcopenia."

Professor Kim Kwangil from the Department of Geriatrics at Seoul National University Bundang Hospital commented, "Sarcopenia is a serious disease that threatens the health of the elderly, but there is still no clear treatment available. If innovative digital therapeutic platforms like DEX-2 are combined with new sarcopenia drugs currently under development, it could create a powerful synergy that transforms the treatment paradigm."

Meanwhile, this study is being conducted with support from the Ministry of Trade, Industry and Energy's Bio Industry Technology Development Project, and will be carried out as a multi-center clinical trial recruiting participants at Seoul National University Bundang Hospital and other institutions, including Seoul Metropolitan Boramae Hospital operated by Seoul National University Hospital.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.